BELRAPZO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BELRAPZO (BELRAPZO).
BELRAPZO (bendamustine hydrochloride) is a bifunctional mechlorethamine derivative that alkylates and crosslinks DNA, leading to cell death. It also exhibits purine analog-like properties, inhibiting DNA synthesis and repair.
| Metabolism | Bendamustine is primarily metabolized via hydrolysis to monohydroxy and dihydroxy metabolites. Minor metabolism occurs via CYP1A2 to form other active metabolites. The drug and its metabolites are mainly excreted in urine. |
| Excretion | Primarily renal excretion: ~70-80% of administered dose excreted unchanged in urine; minor biliary/fecal elimination (<5%). |
| Half-life | Terminal elimination half-life is approximately 1-2 minutes (rapid plasma clearance due to carboxylesterase-mediated hydrolysis). |
| Protein binding | Bendamustine binds to plasma proteins, primarily albumin and alpha-1-acid glycoprotein; protein binding is approximately 94-96%. |
| Volume of Distribution | Volume of distribution: ~0.2-0.3 L/kg for bendamustine; indicates distribution primarily in extracellular fluid and minimal tissue penetration. |
| Bioavailability | Intravenous: 100% bioavailability; not available for oral administration. |
| Onset of Action | Intravenous: Immediate (within 1 minute) due to direct release of bendamustine active metabolites. |
| Duration of Action | Duration of cytotoxic effect: 30-60 minutes; clinical effect (myelosuppression) may persist for weeks due to DNA damage repair kinetics. |
| Molecular Weight | 394.32 Da (bendamustine hydrochloride) |
260 mg/m2 intravenously every 21 days.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment recommended for mild to moderate renal impairment (CrCl ≥30 mL/min). Insufficient data for severe impairment (CrCl <30 mL/min) or ESRD; use with caution. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 200 mg/m2. Child-Pugh C: not recommended. |
| Pediatric use | Safety and efficacy not established in pediatric patients; no recommended dose. |
| Geriatric use | No specific dose adjustment; monitor for increased toxicity due to age-related renal function decline. |
| 1st trimester | Bendamustine is contraindicated in the first trimester due to teratogenicity. Inadvertent exposure requires counseling. |
| 2nd trimester | Avoid use in second trimester unless no alternative. May cause fetal toxicity. |
| 3rd trimester | Avoid use in third trimester; may cause neonatal myelosuppression and adverse effects. |
Clinical note
Comprehensive clinical and safety monograph for BELRAPZO (BELRAPZO).
| Placental transfer | Bendamustine and its metabolites cross the placenta. Animal studies show embryotoxicity and teratogenicity; human data are lacking but similar risk is assumed. |
| Breastfeeding | It is unknown if bendamustine is excreted in human milk. Due to potential for serious adverse reactions in nursing infants, breastfeeding should be discontinued during treatment and for at least 1 week after the last dose. |
■ FDA Black Box Warning
WARNING: EXTRAVASATION INJURY, MYELOSUPPRESSION, INFECTIONS, and HEPATOTOXICITY. See full prescribing information for complete boxed warning. Bendamustine can cause extravasation injury, myelosuppression (severe and prolonged), life-threatening infections, and hepatotoxicity.
| Serious Effects |
Known hypersensitivity to bendamustine or mannitolActive infectionSevere hepatic impairment (bilirubin >2.5 mg/dL)Severe renal impairment (CrCl <30 mL/min)
| Precautions | Myelosuppression: Severe and prolonged neutropenia, thrombocytopenia, and anemia; monitor blood counts., Infection: Serious and fatal infections including opportunistic infections., Hepatotoxicity: Fatal hepatic injury reported; monitor liver function., Extravasation: Ensure proper administration; if extravasation occurs, stop infusion and manage appropriately., Skin reactions: Severe skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis., Tumor lysis syndrome: Risk in patients with high tumor burden; monitor and take preventive measures., Fetal harm: Can cause fetal harm; advise women of reproductive potential to use effective contraception. |
| Food/Dietary |
Loading safety data…
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | BELRAPZO (bendamustine hydrochloride) is classified as Pregnancy Category D. There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans. Exposure during the first trimester is associated with an increased risk of spontaneous abortion and major birth defects. During the second and third trimesters, exposure may cause fetal growth restriction, bone marrow suppression, and developmental delay. Bendamustine is embryotoxic and teratogenic in animal studies. |
| Fetal Monitoring | Monitor complete blood counts (CBC) with differential weekly during treatment and as clinically indicated for myelosuppression. Assess liver function tests (LFTs) and renal function periodically. Monitor for signs of infection, bleeding, and tumor lysis syndrome. Fetal monitoring should include ultrasound for growth and amniotic fluid volume if used during pregnancy. |
| Fertility Effects | Bendamustine may impair fertility in males and females. In females, it can cause amenorrhea, premature ovarian failure, and reduced ovarian reserve. In males, oligospermia, azoospermia, and testicular atrophy may occur, which may be irreversible. Effects on fertility are dose- and duration-dependent. |
| No specific dietary restrictions. However, patients should maintain adequate hydration. Grapefruit juice has not been reported to interact, but caution with alcohol due to potential hepatotoxicity. |
| Clinical Pearls | BELRAPZO (bendamustine) is a bifunctional mechlorethamine derivative used for CLL and NHL. Administer as a 30-minute IV infusion. Premedicate with antiemetics. Monitor for infusion reactions, myelosuppression, and tumor lysis syndrome. Avoid live vaccines during and after treatment. Dose reduction recommended for moderate hepatic impairment. |
| Patient Advice | Notify your healthcare provider immediately if you experience fever, chills, or signs of infection. · You will need regular blood tests to monitor your blood cell counts. · Avoid pregnancy and breastfeeding while on this medication; use effective contraception. · Report any unusual bleeding or bruising to your doctor. · Stay hydrated and inform your doctor if you have nausea, vomiting, or decreased urine output. · Do not receive any live vaccines without consulting your oncologist. |